Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / United Kingdom

Generic Competition And Price Pressures Lead To Lacklustre Q411 Financial Performance

February 2012 | Industry Trend Analysis

BMI View: The continued global generic competition to Nexium (esomeprazole) and the upcoming patent expiry for Seroquel (quetiapine) (March 2012 in the US) will test AstraZeneca's strength in 2012. We believe this, in addition to government price pressures restricting the company's revenue stream in US and Western Europe, point to poor sales in 2012.

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles
Clinical Trials Environment Declining

Industry / United Kingdom BMI Core View: Governments in developed states need to work to maintain the countries' long-term attractiveness as sites for clinical trials, especially as the cost of conducting clinical research is forecast...
June 2011
GSK's Benlysta Approved - What is Next?

Industry / United Kingdom BMI View: The long-term value of any pharmaceutical company will be driven by maintaining internal research and development (R&D) productivity to ensure a steady rate of product launches, with medicines...
May 2011
AstraZeneca's Underperformance To Continue

Industry / United Kingdom BMI View: AstraZeneca's Q111 results highlight its high exposure to healthcare sector cost-containment programmes and pricing pressures placed on medicines by governments in developed states, in addition...
May 2011
AstraZeneca To Divest Medical Devices Division

Industry / United Kingdom BMI View: Drugmakers targeting a wide range of therapeutic areas and diversifying their product range will significantly enhance their long-term growth opportunities. Moreover, by expanding their presence...
November 2010
Brillique: A Threat To Plavix And Effient

Industry / United Kingdom BMI View: The importance of maintaining healthy research and development (R&D) pipelines and launching new drugs by innovative drugmakers cannot be stressed
September 2010
Western Europe InsightWestern Europe Channels Western Europe Countries


All material on this site is protected by international copyright laws and use of this site is subject to our Terms & Conditions.
© 2012 Business Monitor International Ltd
Site powered by WORKSsitebuilder CMS